Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: An initiative of the International Society of Hypertension

Sonali Rukshana Gnanenthiran, Claudio Borghi, Dylan Burger, Fadi Charchar, Neil R. Poulter, Markus P. Schlaich, Ulrike Muscha Steckelings, George Stergiou, MacIej Tomaszewski, Thomas Unger, Richard D. Wainford, Bryan Williams, Anthony Rodgers, Aletta E. Schutte

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Introduction Whether ACE inhibitors (ACEi) or angiotensin II receptor blocker (ARB) therapy should be continued, initiated or ceased in patients with COVID-19 is uncertain. Given the widespread use of ACEi/ARBs worldwide, guidance on the use of these drugs is urgently needed. This prospective meta-analysis aims to pool data from randomised controlled trials (RCTs) to assess the safety and efficacy of ACEi/ARB therapy in adults infected with SARS-CoV-2. Methods and analysis RCTs will be eligible if they compare patients with COVID-19 randomised to ACEi/ARB continuation or commencement versuss no ACEi/ARB therapy; study duration ≥14 days; recruitment completed between March 2020 and May 2021. The primary outcome will be all-cause mortality at ≤30 days. Secondary outcomes will include mechanical ventilation, admission to intensive care or cardiovascular events at short-term follow-up (≤30 days) and all-cause mortality at longer-term follow-up (>1 month). Prespecified subgroup analyses will assess the effect of sex; age; comorbidities; smoking status; ethnicity; country of origin on all-cause mortality. A search of ClinicalTrials.gov has been performed, which will be followed by a formal search of trial registers, preprint servers, MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials to identify RCTs that meet inclusion criteria. To date, a search of ClinicalTrials.gov identified 21 potentially eligible trials for this meta-analysis. We will request trial investigators/sponsors to contribute standardised grouped tabular outcome data. Ethics and dissemination Ethics approval and informed consent will be the responsibility of the individual RCTs. Dissemination of results will occur by peer-reviewed publication. The results of our analysis can inform public health policy and clinical decision making regarding ACEi/ARB use in patients with COVID-19 on a global scale.

Original languageEnglish
Article numbere043625
JournalBMJ Open
Volume11
Issue number2
DOIs
Publication statusPublished - 16 Feb 2021

Keywords

  • COVID-19
  • cardiology
  • hypertension

Fingerprint Dive into the research topics of 'Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: An initiative of the International Society of Hypertension'. Together they form a unique fingerprint.

Cite this